Liquidia Co. (NASDAQ:LQDA) Receives $25.38 Average Price Target from Brokerages

Shares of Liquidia Co. (NASDAQ:LQDA - Get Free Report) have been given a consensus recommendation of "Buy" by the nine ratings firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $25.38.

Several equities research analysts have commented on LQDA shares. Needham & Company LLC restated a "buy" rating and set a $19.00 price target on shares of Liquidia in a research note on Thursday, January 9th. HC Wainwright restated a "buy" rating and set a $29.00 price target on shares of Liquidia in a research note on Thursday, November 14th. Scotiabank started coverage on Liquidia in a research note on Wednesday, October 16th. They set a "sector outperform" rating and a $30.00 price target for the company. Finally, Wells Fargo & Company started coverage on Liquidia in a research note on Friday, December 20th. They set an "overweight" rating and a $20.00 price target for the company.

Insider Activity

In related news, insider Rajeev Saggar sold 2,445 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $13.00, for a total value of $31,785.00. Following the completion of the transaction, the insider now owns 267,943 shares of the company's stock, valued at approximately $3,483,259. This represents a 0.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, General Counsel Russell Schundler sold 16,393 shares of the stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total value of $193,109.54. Following the completion of the transaction, the general counsel now directly owns 573,478 shares of the company's stock, valued at $6,755,570.84. This represents a 2.78 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 73,945 shares of company stock worth $874,403. 30.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of LQDA. Whitefort Capital Management LP boosted its holdings in Liquidia by 119.8% in the third quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company's stock valued at $17,020,000 after purchasing an additional 927,546 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Liquidia by 144.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company's stock worth $3,903,000 after buying an additional 230,820 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Liquidia by 855.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 235,393 shares of the company's stock worth $2,354,000 after buying an additional 210,753 shares during the last quarter. Anson Funds Management LP bought a new position in Liquidia during the 3rd quarter worth approximately $1,764,000. Finally, Sapient Capital LLC bought a new position in Liquidia during the 3rd quarter worth approximately $1,336,000. Hedge funds and other institutional investors own 64.54% of the company's stock.

Liquidia Stock Performance

Liquidia stock traded down $0.21 during trading on Wednesday, hitting $15.75. The company's stock had a trading volume of 808,493 shares, compared to its average volume of 914,700. The stock has a market capitalization of $1.33 billion, a price-to-earnings ratio of -9.66 and a beta of 0.27. The stock's fifty day moving average is $12.45 and its 200 day moving average is $11.29. Liquidia has a 1-year low of $8.26 and a 1-year high of $16.99.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).